
==== Front
J Nanobiotechnology
J Nanobiotechnology
Journal of Nanobiotechnology
1477-3155
BioMed Central London

39238020
2813
10.1186/s12951-024-02813-w
Research
GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor
Huang Chenlu 12
Yang Xinyu 12
Li Huidong 2
Zhang Li 12
Guo Qing 12
Yu Qingyu 12
Wang Hai 12
Zhang Linhua zhanglinhua@bme.pumc.edu.cn

12
Zhu Dunwan zhudunwan@bme.pumc.edu.cn

12
1 https://ror.org/02drdmm93 grid.506261.6 0000 0001 0706 7839 State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192 China
2 https://ror.org/02ke5vh78 grid.410626.7 0000 0004 1798 9265 Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, 300100 China
5 9 2024
5 9 2024
2024
22 5426 7 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Phototherapy is a promising antitumor modality, which consists of photothermal therapy (PTT) and photodynamic therapy (PDT). However, the efficacy of phototherapy is dramatically hampered by local hypoxia in tumors, overexpression of indoleamine 2,3-dioxygenase (IDO) and programmed cell death ligand-1 (PD-L1) on tumor cells. To address these issues, self-assembled multifunctional polymeric micelles (RIMNA) were developed to co-deliver photosensitizer indocyanine green (ICG), oxygenator MnO2, IDO inhibitor NLG919, and toll-like receptor 4 agonist monophosphoryl lipid A (MPLA). It is worth noting that RIMNA polymeric micelles had good stability, uniform morphology, superior biocompatibility, and intensified PTT/PDT effect. What’s more, RIMNA-mediated IDO inhibition combined with programmed death receptor-1 (PD-1)/PD-L1 blockade considerably improved immunosuppression and promoted immune activation. RIMNA-based photoimmunotherapy synergized with PD-1 antibody could remarkably inhibit primary tumor proliferation, as well as stimulate the immunity to greatly suppress lung metastasis and distant tumor growth. This study offers an efficient method to reinforce the efficacy of phototherapy and alleviate immunosuppression, thereby bringing clinical benefits to cancer treatment.

Graphical Abstract

Supplementary Information

The online version contains supplementary material available at 10.1186/s12951-024-02813-w.

Keywords

Polymeric micelles
Phototherapy
Immunotherapy
Indoleamine 2,3-dioxygenase (IDO)
Immune checkpoint inhibitor
Hypoxic tumor microenvironment
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82302390 82072059 82172090 http://dx.doi.org/10.13039/501100002858 China Postdoctoral Science Foundation 2022M720502 http://dx.doi.org/10.13039/501100006606 Natural Science Foundation of Tianjin Municipality 22JCQNJC00070 CAMS Union Young Scholars Support Program2022051 CAMS Innovation Fund for Medical Sciences2021-I2M-1-058 2021-I2M-1-058 http://dx.doi.org/10.13039/501100012226 Fundamental Research Funds for the Central Universities 2019PT320028 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Multimodal synergistic therapy that integrates the advantages of single therapy exhibits a remarkable super-sum effect and great prospects for development in tumor treatment [1]. The advent of nanotechnology offers unprecedented foreground for multimodal synergistic therapies, which can consolidate therapeutics with different functions into a single nanosystem to produce significant antitumor efficacy [2–5]. Phototherapy, consisting of photothermal therapy (PTT) and photodynamic therapy (PDT), has become a promising tumor treatment modality due to its strengths of less drug resistance, rapid healing and good efficacy [6]. The combined strategy of PTT and PDT can realize better treatment outcomes with fewer photosensitizer doses, lower irradiation power, and shorter treatment duration, as well as less side effects on normal tissues [7, 8]. PTT-mediated hyperthermia can boost the permeability of cell membranes and enhance the uptake of photosensitizer-loaded nanocarriers by tumor cells as well as improve local blood flow and increase the O2 concentration in tumor tissues, thus promoting the generation of reactive oxygen species (ROS) [9, 10]. In turn, ROS produced during PDT can destroy heat shock proteins, thereby weakening their protective effect on tumor cells during PTT [11, 12]. As an near-infrared (NIR) fluorescent dye, indocyanine green (ICG) is approved by U.S. Food and Drug Administration (FDA) one and only for in vivo applications and also acts as a photosensitizer [13]. Although ICG-loaded nanocarriers improve some shortcomings of free ICG, such as easy aggregation, low ROS yield, and poor stability [14]. However, its efficacy of PDT is dramatically reduced due to the hypoxic microenvironment in the tumor [15, 16]. To overcome this problem, MnO2 is introduced to catalyze the formation of O2 from overexpressed H2O2 in the tumor microenvironment (TME), thereby generating sufficient ROS during ICG-mediated PDT to induce apoptosis of tumor cells [17–19]. Phototherapy can effectively inhibit the primary tumor, but it is difficult to restrain the metastasis and recurrence of the tumor [20].

Metastatic tumor that spreads to distant organs accounts for more than 90% of tumor-related deaths [21]. At present, the two biggest challenges in clinical tumor treatment are to prevent the metastasis of local tumor and avoid recurrence [22]. To settle these problems, better treatments must be developed to kill tumor cells extensively and completely. Tumor immunotherapy is a method that can prevent the metastatic spread of local tumor and avoid recurrence by boosting the immune system to identify and kill tumor cells [23]. Although PTT and PDT have been reported to produce tumor-associated antigens (TAAs) and activate acute inflammation to evoke tumor-specific immunity, the efficacy of antitumor immunity is limited [24]. Tumor cells evade the recognition by the immune system due to various immune-negative regulatory signals that inhibit T cell activation, which may be the reason for the failure of antitumor immunotherapy [25]. Therefore, one of the most effective tactics is inhibition of negative immunomodulation to reactivate the antitumor immune response [25–27]. Tumor cells overexpress indoleamine 2,3-dioxygenase (IDO), which is in charge of catalyzing the transition of tryptophan (Trp) to kynurenine (Kyn), subsequently promotes the expansion of immunosuppressive regulatory T cells (Tregs) and inhibits the proliferation and activation of antitumor effector T cells, thus facilitating the immune escape of tumor cells in the TME [28–30]. In addition, programmed cell death ligand-1 (PD-L1) overexpressed on tumor cells binds to programmed death receptor-1 (PD-1) on T cells to induce exhaustion of T cell, which also grants tumor cells to avoid immune surveillance [31, 32]. Considering the immune escape pathway, several immune checkpoint inhibitors of IDO and PD-1/PD-L1 have been exploited to reprogram the immunosuppressive microenvironment in preclinical and clinical trials [33]. Nevertheless, phase III clinical trials of IDO inhibitors have failed [34], and the clinical response rate to PD-1/PD-L1 blockade is only 10%~30% [35]. Rational combination therapy strategies have attracted widespread attention by transforming “cold” tumors into “hot” tumors to trigger infiltration of T cell into tumors through various methods (e.g. chemotherapy, radiotherapy, phototherapy, etc.) [36–39].

Herein, we fabricated multifunctional polymeric micelles (Arginylglycylaspartic acid (RGD)-ICG/MnO2/NLG919/monophosphoryl lipid A (MPLA)@polymeric micelles, labeled as RIMNA) for the synergistic treatment of enhanced PTT-PDT-immunotherapy. RIMNA polymeric micelles loaded with photosensitizer ICG, oxygenator MnO2 and IDO inhibitor NLG919 were synthesized by thin-film hydration plus sonication method, as well as toll-like receptor (TLR) 4 agonist MPLA were inserted on the surface. As shown in Scheme 1, the treatment strategy was mainly conducted via the steps as follows: (1) RIMNA polymeric micelles accumulated into the tumor after systemic administration, then responded to NIR laser and high glutathione (GSH) in TME to release drugs. (2) The excess H2O2 in TME provided sufficient substrate for MnO2 exerting an enzymatic reaction to produce O2, which could ameliorate the hypoxic status in tumors and promote PDT efficacy. Besides, MnO2 also enhanced the PTT effect of ICG. (3) Under NIR laser irradiation, RIMNA polymeric micelles killed primary tumors by PDT/PTT synergistic treatment, as well as released TAAs. (4) TAAs and MPLA were absorbed by immature dendritic cells (DCs) and induced DCs maturation, thereby activating antitumor immune responses. (5) Subsequently, the IDO-mediated Trp/Kyn immune escape pathway was blocked by NLG919, which reduced Tregs ratio and strengthened the function of effector T cells. (6) PD-1 blockade antibody further improved tumor-specific immune responses, prevented distant tumors growth and lung metastasis. RIMNA-based photoimmunotherapy in combination with PD-1 blockade antibody offered a promising strategy to fight tumor.

2. Materials and methods

2.1. Preparation of RIMNA

The polymeric micelles RIMNA were prepared using thin-film hydration plus sonication method based on polyethylene polycaprolactone-ss-polyethylene glycol-ss-polyethylene polycaprolactone (PCL-ss-PEG-ss-PCL) copolymer synthesized by our research group. First, MnO2 and hydrophobic ICG were fabricated according to the previous literature [40]. Next, PCL-ss-PEG-ss-PCL (20 mg), ICG (1 mg), DSPE-PEG-COOH (1 mg), NLG919 (1 mg), MPLA (20 µg) and MnO2 (0.2 mg) were dissolved in an eggplant bottle with dichloromethane and sonicated for 5 min. Then a thin film was obtained by rotary evaporation to remove dichloromethane and hydrated at 65 °C drying oven for 5 h. Subsequently, the mixture was sonicated using a probe sonicator in ice bath for 10 min and dialyzed with deionized water to remove free drugs. Finally, RIMNA was acquired after NH2-RGD ligation by 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (EDC)/N-Hydroxysuccinimide (NHS) activation reaction. RINA (without MnO2 loading), RIMA (without NLG919 loading), and RIMN (without MPLA loading) were formulated by the similar methods as depicted above.

Cellular uptake study in vitro

CT26 cells were cultured in confocal plates overnight and fresh roswell park memorial institute (RPMI) 1640 medium containing Free ICG, RINA, and RIMNA (ICG: 10 µg/mL) were added. After co-incubation for 2 h, the cells were irradiated with 808 nm laser (1.5 W/cm2, 5 min). After incubation for another 2 h, confocal laser scanning microscope (CLSM, Zeiss LSM 710, Jena, Germany) was used to observe the cells after Hoechst staining.

Intracellular ROS generation assay in vitro

Phosphate buffer saline (PBS), RINA, and RIMNA were co-cultured with CT26 cells for 2 h (ICG: 10 µg/mL). Next, the cells were incubated with 2’,7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) for 15 min at 37 ℃. Then the cells were washed once with PBS and irradiated with 808 nm laser for 5 min (1.5 W/cm2). Intracellular ROS levels were detected by CLSM and flow cytometry (BD FACS Calibur, USA).

Cytotoxicity assay in vitro

CT26 cells were inoculated into 96-well plates and co-incubated with RIMNA, RINA, and Free ICG (ICG equivalent concentration was 2.5, 5, 10 and 20 µg/mL) for 24 h. In the laser irradiation group, the cells were irradiated with 808 nm laser for 5 min (1.5 W/cm2). After that, 100 µL RPMI1640 medium mixed with CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (20 µL of MTS in every 100 µL RPMI1640 medium) was added to each well, and the cells were incubated in the incubator for 30 min followed by being assessed with a Varioskan Flash Multimode Reader (Thermo Fisher Scientific, USA).

IDO inhibition

CT26 cells (1.5 × 104) were seeded into a 24-well plate, and 50 ng/mL of interferon (IFN)-γ was added into each well and incubated overnight to stimulate the IDO expression. After that, the cells were co-cultured with PBS, NLG919, RIMA, RIMNA and RIMNA + Laser (the concentration of NLG919 was 5 µg/mL) for 24 h, respectively. After incubation for 2 h, the cells treated with RIMNA + Laser were irradiated with 808 nm laser (1.5 W/cm2, 5 min) and co-incubated for another 22 h. After that, the supernatants were collected and the contents of Kyn and Trp were measured with enzyme linked immunosorbent assay (ELISA) kits.

Tumor accumulation study in vivo

CT26 cells (1 × 106) were inoculated into the right buttock of female BALB/c mice (6–8 weeks old) to establish CT26 tumor-bearing mouse model. When the tumors grew to ∼200 mm3, the mice were randomly divided into RIMNA, Free ICG and PBS groups to observe the tumor accumulation of polymeric micelles after intravenous administration (ICG dose: 5 mg/kg, n = 5). In vivo imaging was performed at 6, 12, 24, 48 and 72 h post injection.

PTT-PDT synergistic antitumor study in vivo

CT26 cells (1 × 106) were injected subcutaneously in the right buttock of BALB/c mice (6–8 weeks old) on day 0. And the mice were divided into 4 groups on day 7: (1) RIMNA + Laser; (2) RINA + Laser; (3) Free ICG + Laser; (4) PBS + Laser (ICG dose: 5 mg/kg), of which the tumors received 808 nm laser (1.5 W/cm2) for 5 min at 24 h and 48 h after tail vein intravenous administration every 5 days and observed with Fluke infrared imaging device to record the temperature change. Finally, the treated mice were sacrificed to collect the tumor and major organs from all groups for hematoxylin and eosin (H&E) analysis on day 15. And the hypoxia and ROS generation of tumor cells were investigated via immunofluorescence staining methods. For the hypoxia study, after intraperitoneal injection of pimonidazole hydrochloride 1.5 h into the mice, the tumors were collected and sliced into sections. The tumor sections were blocked by 10% donkey serum and incubated with hyproxyprobe-1 and FITC-labeled anti-IgG (H + L) second antibody following the manufacturer’s instructions. For the ROS level study, the tumors were irradiated with 808 nm laser (1.5 W/cm2, 5 min) after dichlorodihydrofluorescein diacetate (DCFH-DA) intratumorally injected into the mice for 2 h. Then the tumor tissues were collected and sliced into sections. All the sections were stained with DAPI before being detected by CLSM.

Abscopal effect study

The tumor-bearing mouse models were established by inoculating CT26 cells (1 × 106) into the right flank of the BALB/c mice on day 0. CT26 cells (2 × 105) were inoculated into the left flank on day 6. Once the volumes of primary tumors reached about 80 mm3 on day 7, RIMNA, RINA, RIMA, RIMN, I + N + A, and PBS (ICG dose: 5 mg/kg, n = 5) was intravenously (i.v.) injected to the mice, respectively. These treatments were operated twice with an interval of 5 days. At 24 and 48 h after intravenous injection, the primary tumors of the mice were irradiated with 808 nm laser (1.5 W/cm2, 5 min). 100 µg aPD-1 was injected intraperitoneally every 3 days for 4 times [41]. The tumor volumes and body weights of mice were noted every two days. The tumor volume (V) was calculated by using the equation: V = 0.5 × length × width2. When the tumor volumes reached 2000 mm3, the mice were ethically required to be euthanized.

Immune responses study

On day 21, spleens, tumor-draining lymph nodes, and tumors of the treated mice were harvested and prepared into single-cell suspensions. The obtained single cells were co-marked with anti-CD11c, anti-CD80, anti-CD40, and anti-CD86 antibodies for analyzing the mature DCs; co-stained with anti-CD3, anti-CD4, and anti-CD8 antibodies for analyzing the CD4+ and CD8+ T cells; co-marked with anti-CD4, anti-CD8, and anti-CD69 antibodies for analyzing the activation of CD4+ and CD8+ T cells; co-marked with anti-CD4, anti-CD8, and anti-IFN-γ antibodies for analyzing the IFN-γ-secreting T cells; co-marked with anti-CD4 and anti-Foxp3 antibodies for the analysis of the Tregs; and co-marked with anti-CD4, anti-CD8, anti-CD44, and anti-CD62L antibodies to measure the central memory T cells according to the procedures of the manufacturer by using flow cytometry. Meanwhile, the sera were also collected to detect tumor necrosis factor-α (TNF-α) and interleukin-4 (IL-4) through ELISA kits.

Tumor metastasis inhibition

The mice treated as described in part “Abscopal effect study” received tail vein injection of CT26 cells (1 × 105) on day 20. For analyzing metastasis, the lungs were collected and prepared for H&E staining on day 30.

Statistical analysis

All data were displayed as mean ± standard error of mean (SEM). All statistical analyses were presented using GraphPad Prism by one-way or two-way analysis of variance (ANOVA) and P < 0.05 was considered statistically significant.

Results and discussion

Preparation and characterization

Multifunctional polymeric micelles (RIMNA) with phospholipid layer and drug loaded core were constructed using thin-film hydration plus sonication method to encapsulate photosensitizer ICG, oxygenator MnO2, IDO inhibitor (NLG919), and TLR4 agonist MPLA. The transmission electron microscopy (TEM) images of RIMNA presented regular spherical shape (Fig. 1A). The average hydrodynamic diameter and zeta potential of RIMNA were 161.87 ± 4.14 nm and − 22.3 ± 0.01 mV, respectively. And the particle size of RIMNA was between 160 and 180 nm and kept steady within 7 days, which was able to realize high accumulation into the tumor site via enhanced permeability and retention (EPR) effect (Fig. 1B) [42]. Dynamic light scattering (DLS) further showed that RIMNA had a homogeneous distribution with a narrow dispersion in PBS solution (pH 7.4) (Fig. 1C). Besides, we detected the particle size change of RIMNA in GSH solution to verify the reduction sensitivity. The results showed that there were two broad peaks in the presence of GSH, suggesting that -ss- was destroyed to cause the fragmentation of RIMNA under reductive condition. The ultraviolet-visible (UV-vis) absorption spectra revealed that the characteristic absorption peak of ICG and NLG919 were at ~ 780 nm and ~ 280 nm, respectively, which indicated the successful loading of ICG and NLG919 in RIMNA (Fig. 1D). The photothermal efficiency of RIMNA was also studied in Fig. 1E and F, and the results demonstrated that the temperature rise of RIMNA, RINA, and Free ICG were 53.4 ℃, 50.8 ℃, and 45.8 ℃, respectively. By comparison, PBS solution showed a negligible rising of temperature, indicating that polymeric micelles ameliorated the defect of free ICG and the presence of MnO2 enhanced the PTT effect [43–45].

Cellular uptake, ROS generation, and cytotoxicity in CT26 tumor cells

As shown in Fig. 1G, polymeric micelles enabled enhanced uptake of ICG by CT26 tumor cells. It’s worth mentioning that the cellular uptake of ICG in Free ICG, RINA and RIMNA groups significantly increased when cells exposed to NIR laser irradiation, which may be ascribe to that the temperature elevation enhanced the fluidity and permeability of cell membrane [46]. Next, ROS probe carboxy-H2DCFDA was used to determine the intracellular ROS production. There was almost no ROS produced in the cells dealt with PBS, PBS + Laser or RINA (Fig. 1H). And compared with non-laser irradiation group, the green fluorescence signal of RINA was enhanced after laser irradiation. The cells incubated with RIMNA exhibited weak ROS fluorescence [47], and the intracellular ROS signals dramatically augmented when the laser irradiation was carried out. What’s more, the flow cytometry histograms displayed the similar results to the CLSM images, which demonstrated that both laser irradiation and the introduction of MnO2 improved the level of intracellular ROS (Fig. 1I).

PEG/PCL copolymers approved by the U.S. FDA have been extensively explored as potential drug delivery vehicles, which is non-toxic and biocompatible [48]. As an NIR fluorescent dye, ICG is approved by the U.S. FDA for clinical use [49]. MTS assay was used to evaluate the biocompatibility of polymeric micelles and phototherapy-caused cytotoxicity of RIMNA (Fig. 1J and K). RINA exhibited no damage to CT26 cells, indicating polymeric micelles were biocompatible and safe. The slight cytotoxicity of RIMNA at high concentrations may be the results of MnO2-mediated Fenton reaction [50]. RIMNA, RINA, and Free ICG all exhibited concentration-dependent phototoxicity to CT26 cells under laser irradiation. When the concentration of ICG reached 10 µg/mL, the cell survival rate treated with RINA + Laser group was about 50%, while that of RIMNA + Laser group decreased significantly to about 20%. Therefore, RIMNA plus laser irradiation could effectively kill tumor cells through PTT-PDT effects. To detect the inhibitory effect of RIMNA on IDO pathway, CT26 cells were treated with PBS, NLG919, RIMA, RIMNA and RIMNA + Laser, and the contents of Kyn and Trp were measured with ELISA kits. As shown in Fig. S1 (Supporting Information), the ratio of Kyn to Trp treated with NLG919 exhibited an apparent decline. Compared with PBS and RIMA groups, the ratio of Kyn to Trp in RIMNA and RIMNA + Laser treated group decreased greatly, demonstrating the inhibition effect of RIMNA polymeric micelles on IDO signal pathway caused by NLG919.

3.3. Tumor accumulation in vivo

In vivo imaging was proceeded to surveillance the accumulation of polymeric micelles after intravenous administration. CT26 tumor-bearing mice of the three groups (PBS, Free ICG, and RIMNA) were tracked at 6, 12, 24, 48, and 72 h post injection (Supporting Information Fig. S2). For the PBS group, no signal was observed at each time point. The signal of Free ICG was found at 6 h, while negligible signal was observed after 48 h because of the rapid metabolism of ICG. In contrast, the fluorescence of RIMNA was stronger than that of Free ICG at all time points, and the maximum accumulation of ICG at the tumor site was attained after 24 h of intravenous administration, proving that EPR effect based on polymeric micelles could facilitate tumor accumulation [51].

PTT-PDT effect in vivo

The antitumor capacity of RIMNA-based PTT-PDT was estimated through CT26 subcutaneous tumor model and the schematic illustration of the treatment plan was displayed in Fig. 2A. CT26 tumor-bearing mice were irradiated with 808 nm laser (1.5 W/cm2) at 24 h and 48 h after administration of PBS, Free ICG, RINA, and RIMNA. The PBS group induced the least change in temperature even being irradiated for 5 min (Fig. 2B-D). The Free ICG group showed an ineffective temperature elevation (below 44 °C) due to poor stability, short retention time, high clearance rate, and less tumor accumulation [14]. An enhanced photothermal conversion effect was observed in RINA treatment group, and the temperature of tumor increased to 51.3 °C. Surprisingly, owing to the MnO2-enhanced PTT effect, the RIMNA group showed a dramatic temperature increase to 54.9 °C, demonstrating its favorable photothermal capacity. Notably, even after 48 h of intravenous injection, the tumor site achieved 54.1 °C under laser irradiation, which illustrated RIMNA enhanced the in vivo stability and intratumoral accumulation of ICG. Furthermore, we investigated hypoxia of tumor tissues via immune-fluorescence staining methods. Hyproxyprobe-1 combined with anti-FITC antibody were applied to evaluate the hypoxia status in tumor. As an oxygen sensitive fluorescent probe, the design of hyproxyprobe-1 is based on oxygen sensitive fluorescent dyes. In hypoxic environment, nitroimidazole in the hyproxyprobe-1 reduced by the nitroreductase in the cell to emit green fluorescence, and the fluorescence intensity deepens with the increase of the degree of hypoxia. Large areas of green fluorescence represented for hypoxia was remarked in the PBS + Laser and Free ICG + Laser treated group (Fig. 2E). The hypoxia status of the tumor in the RINA + Laser treated group was slightly relieved, which may be due to that sufficient hyperthermia accelerated blood flow and increased intravascular O2 concentration in tumor tissues [1, 52]. Especially there was very little green fluorescence in RIMNA + Laser group, suggesting that MnO2 catalyzed the generation of O2 and relieved the hypoxia of tumor tissues. As shown in Fig. 2F, there was no visible green fluorescence indicated ROS in the PBS + Laser treated group, demonstrating that 808 nm laser irradiation alone couldn’t generate ROS. The green fluorescence in Free ICG + Laser group and RINA + Laser group was faint, while that in the RIMNA + Laser group was strong, indicating that MnO2-mediated tumor hypoxia amelioration significantly reinforced PDT effect. Tumor apoptosis via PTT-PDT was detected through H&E staining methods. The most necrosis tumor cells could be observed in RIMNA + Laser group, implying the enhanced PTT-PDT combined effect promoted tumor apoptosis (Fig. 2G). Besides, H&E images demonstrated that there was no obvious histopathological damage of major organ tissues (Supporting Information Fig. S3), proving the good biocompatibility of RIMNA.

Immune responses in vivo

DCs play a key role in the initiation and moderation of innate and adaptive immunities [53, 54]. To test whether RIMNA plus NIR irradiation could induce DCs maturation for initial immune response in vivo, tumor-draining lymph nodes were removed and stained. The results demonstrated that the expression levels of CD40, CD80, and CD86 on the surface of DCs were notably reinforced in the groups treated by RIMNA + Laser compared with other groups (Fig. 3A-F). RIMNA-based photoimmunotherapy could induce the largest amount of TAAs production, combined with the immunostimulatory effect of MPLA, promoting the highest maturation and stimulation level of DCs.

We further estimated the effect of RIMNA + Laser on tumor immune microenvironment and systemic immune activation by detecting cytotoxic T lymphocytes (CTLs) and T helper cells (Ths) in tumor and spleen. CTLs (CD3+CD8+) and Ths (CD3+CD4+) are vital parts of the adaptive immunity, which kill tumor cells directly or activate the immune cells [55]. As shown in Fig. 4A and B, RIMNA + Laser treatment enhanced the intratumoral infiltration of CTLs and Ths, which resulted in a pronounced increase of CD3+CD8+ and CD3+CD4+ T cells to 18.4% and 11.3%, respectively. These results were supposed to be that MnO2 loaded in RIMNA alleviated hypoxic status in tumor and reprogrammed the immunosuppressive environment, together with RIMNA polymeric micelles-mediated phototherapy, achieved potent antitumor responses. A similar increase of CD3+CD8+ and CD3+CD4+ T cells was also noted in the spleen, where RIMNA + Laser promoted them by 2.25-fold and 1.66-fold compared to PBS + Laser, respectively (Fig. 4C and D), revealing that RIMNA + Laser treatment could stimulate a systemic immune response. These results demonstrated that RIMNA + Laser effectively triggered DCs maturation in vivo to activate a powerful antitumor immune response.

IFN-γ is a proinflammatory cytokine released by immune cells with the functions of inhibiting tumor cell proliferation and stimulating adaptive immunity [56]. The results suggested that the percentages of CD8+IFN-γ+ T cells was 5.21%, 2.04%, 2.38%, 2.86%, 1.71%, and 1.19% in RIMNA + Laser group, RINA + Laser group, RIMA + Laser group, RIMN + Laser group, I + N + A + Laser group, and PBS + Laser group, respectively (Fig. 4E and F). Compared with PBS + Laser treatment (0.25%), RIMN + Laser treatment significantly boosted CD4+ T cells secreting IFN-γ by 10.12-fold (2.53%), while RIMNA + Laser achieved the same aim by an increase of 18.76-fold (4.69%), proving that MPLA as a potent and safe adjuvant is able to bind to TLR4 and form phagosomes for inducing the secretion of proinflammatory cytokines [57]. It is worth pointing out that owing to the inhibition of IDO by NLG919, a notable rise of IFN-γ-secreting CD8+ and CD4+ T cells was monitored in the RIMNA + Laser group compared to RIMA + Laser group.

One of the remarkable features of adaptive immunity mediated by T cells is immune memory response, which plays a crucial role in protecting organisms from the second attack of tumor [58]. To verify whether RIMNA plus laser was able to produce an immune memory effect, the collected splenocytes suspension was stained to calculate central memory T cells (TCM). The results displayed that the percentage of CD8+TCM in RIMNA + Laser group was 50.7% (Supporting Information Fig. S4), which was the highest among all the groups. Similarly, the percentage of CD4+TCM in RIMNA + Laser group was 44.4%, which was remarkably higher than that in RINA + Laser group (34.8%), RIMA + Laser group (33.3%), RIMN + Laser group (31.4%), I + N + A + Laser group (21.5%), and PBS + Laser group (21.3%). Therefore, the above results indicated that RIMNA + Laser treatment could trigger robust immune memory effects.

Abscopal effect of RIMNA-mediated PTT-PDT synergistic immunotherapy

Encouraged by the potent immune activation results of RIMNA + Laser treatment, we further explored the antitumor effects in vivo through the bilateral CT26 tumor model by 2 cycles of intravenous injection plus 808 nm laser irradiation every 5 days and intraperitoneal administration of PD-1 antibody on days 8, 11, 14, and 17 (Fig. 5A). RINA + Laser, RIMA + Laser, and RIMN + Laser groups showed moderate tumor inhibition, while RIMNA + Laser significantly eradicated primary tumor (Fig. 5B). It’s also worthy to mention that the inhibition efficacy of distant tumor in RIMNA + Laser group was much better than that of RIMA + Laser and RIMN + Laser treatment, which may be attributed to that the presence of NLG919 and MPLA evoked powerful immune response against distant tumors (Fig. 5C). Further combination of RIMNA + Laser with PD-1 antibody achieved the highest growth inhibition both of primary and distant tumors. It’s worthy noted that complete tumor eradication without recurrence was achieved in all 5 tumor-bearing mice treated with RIMNA + Laser with PD-1 antibody. In contrast, although RIMNA + Laser treatment also obviously prolonged the survival time, all the mice died on day 43 (Fig. 5D). Altogether, the fact verified that RIMNA + Laser with PD-1 antibody had optimal antitumor efficacy, particularly inhibition distant tumors via the abscopal effect. Moreover, the above results also proved that suppressing the activity of Tregs and reactivating CTLs to block the immune escape of tumor cells has been considered a hopeful and effective antitumor strategy [28, 59].

The combination of PD-1 antibody strengthened the immune effect and antitumor metastasis

Inspired by the superior abscopal effect of RIMNA + Laser combined with PD-1 antibody, we next investigated its anti-metastasis mechanism and efficacy. The RIMNA + aPD-1 + Laser group increased the proportions of CTLs and Ths by 2.38- and 2.30-fold compared to PBS + Laser group, respectively (Fig. 6A and B, Supporting Information Fig. S5A and B). It’s worthy noted that higher activation level of CTLs and Ths were observed in the spleens following treatment with RIMNA + aPD-1 + Laser (Fig. 6C and D, Supporting Information Fig. S5C and D). Moreover, RIMNA + aPD-1 + Laser treatment increased the IFN-γ-secreting CTLs ratio by ~ 15.63- and ~ 1.44-fold compared with PBS + Laser and RIMNA + Laser groups, respectively (Fig. 6E and Supporting Information Fig. S5E). Tregs are a subset of T lymphocytes that inhibit the function of effector T cells, leading to tumor development and immunosuppressive TME [55, 60]. RIMNA + aPD-1 + Laser treatment apparently decreased the proportion of Tregs compared with other groups, notably by 1.40-fold compared with PBS + Laser group (Fig. 6F and Supporting Information Fig. S5F). RIMNA + Laser could significantly upregulate the amounts of TNF-α and IL-4 in the sera, and the addition of aPD-1 further promoted these proinflammatory cytokines’ secretion (Fig. 6G and H), indicating a synergistic effect to induce inflammatory response. These results suggested that RIMNA + Laser synergized with aPD-1 efficiently initiated T cell activation in vivo.

As shown in Fig. 6I, no lung nodule was observed in the RIMNA + aPD-1 + Laser group, indicating its desirable anti-metastatic effects. Furthermore, TCM in spleens were quantitatively analyzed with flow cytometry. The proportions of TCM among CD8+ and CD4+ T cells in the RIMNA + aPD-1 + Laser treated group were significantly higher than those in the PBS + Laser group (P < 0.001, Fig. 6J, K and Supporting Information Fig. S5G, H). Overall, those results proved that RIMNA + aPD-1 + Laser could effectively inhibit tumor growth in primary tumor, distant tumor, and pulmonary metastasis models through robust PTT-PDT synergized with immunotherapy.

Conclusions

In conclusion, we designed and developed GSH-responsive polymeric micelles RIMNA with MnO2, NLG919, and MPLA encapsulated for augmented PTT-PDT synergized with immunotherapy. MnO2 was able to improve ROS production via MnO2-catalyzed O2 generation in the H2O2-overexpressed TME, inducing strengthened PDT as well as PTT effects and the release of TAAs. Moreover, MPLA activated the TLR4 pathway to increase the secretion of proinflammatory cytokines and NLG919 inhibited IDO to reduce Tregs, thus enhancing antitumor immune response. Notably, RIMNA also attenuated TME immunosuppression by remarkably promoting the intratumoral infiltration of CTLs and Ths. Further, RIMNA-based PTT-PDT-immunotherapy exhibited excellent efficacy in suppressing the growth of distant tumor and preventing tumor metastasis of colon tumor combined with PD-1 checkpoint blockade. Taken together, this work showed the multifunctional polymeric micelles to elicit effective PTT-PDT and enlarge PTT-PDT-induced immune stimulation for steady antitumor immunity, demonstrating a prospective strategy for tumor therapy.

Scheme 1 Schematic illustration of RIMNA polymeric micelles as amplifier for robust photoimmunotherapy synergized with PD-1 blockade antibody against primary tumors, distant tumors, and lung metastasis

Fig. 1 Characterization and CT26 cell-level evaluation of RIMNA. (A) TEM images of RIMNA (Scale bar = 50–200 nm). (B) The particle size stability of RIMNA stored at 4 °C (n = 3). (C) The particle size distribution of RIMNA in PBS solution (pH 7.4) with or without GSH. (D) The absorption spectra of RIMNA, ICG, and NLG919. (E) Temperature curves and (F) corresponding infrared thermal imageries of RIMNA, RINA, Free ICG, and PBS under NIR laser irradiation. (G) The CLSM images indicated cellular uptake (Scale bar = 20 μm). (H) The CLSM images and (I) representative flow cytometric plots indicated ROS production (Scale bar = 20 μm). The survival rate of CT26 cells incubated with various concentrations of RIMNA, RINA or Free ICG (J) without or (K) with NIR laser irradiation (n = 3)

Fig. 2 PTT-PDT effect in vivo. (A) Schematic diagram of the treatment plan. The temperature change curves of tumor sites at (B) 24 h or (C) 48 h timepoint after administration (n = 3). (D) Representative NIR thermography at 24–48 h timepoint. CLSM images of (E) hypoxia and (F) ROS generation in tumor site after indicated treatments (Scale bar = 50 μm). (G) H&E images of the tumors (Scale bar = 25 μm)

Fig. 3 DCs activation in tumor-draining lymph nodes. Representative flow cytometric plots of (A) CD40, (B) CD80, and (C) CD86 expression on the membrane of DCs from the lymph nodes of CT26 tumor-bearing mice following indicated treatments. Corresponding quantification of (D) CD40, (E) CD80, and (F) CD86 (n = 3). Data were displayed as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001 vs. RIMNA + Laser group)

Fig. 4 Evaluation of systemic antitumor immune. (A, B) The percentages of CTLs and Ths in the tumors through flow cytometric examination (n = 3). (C, D) The percentages of CTLs and Ths in the spleens through flow cytometric examination (n = 3). (E, F) The percentages of IFN-γ-secreting CD3+CD8+ T cells and CD3+CD4+ T cells in the spleens through flow cytometric examination. Data were displayed as mean ± SEM (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001 vs. RIMNA + Laser group)

Fig. 5 Antitumor effects in vivo. (A) Treatment schedule in bilateral CT26 tumor model. Volume changes of (B) primary tumor and (C) distant tumor of mice after indicated treatments. (D) Corresponding survival curves. Data were displayed as mean ± SEM (n = 5, **P < 0.01, ***P < 0.001 vs. RIMNA + aPD-1 + Laser group)

Fig. 6 Anti-metastasis effect. The percentages of (A) CTLs, (B) Ths, (C) CD8+CD69+ T cells, (D) CD4+CD69+ T cells, (E) IFN-γ+CD8+ T cells, and (F) Tregs in splenocytes (n = 3). Quantification of (G) TNF-α and (H) IL-4 released in sera after indicated treatments (n = 3). (I) H&E staining images of lung (Scale bar = 200–50 μm). The percentages of CD44hiCD62Lhi among (J) CD8+ T cells and (K) CD4+ T cells in spleens (n = 3). Data were displayed as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001 vs. RIMNA + aPD-1 + Laser group)

Supplementary Information

Supplementary Material 1: Figure S1 Inhibition of RIMNA polymeric micelles on IDO signal pathway. Data were displayed as mean ± SEM (n  = 3, **P  < 0.01, ***P  < 0.001). Figure S2 Fluorescence images of CT26 tumor-bearing mice after i.v. injection of RIMNA, Free ICG or PBS. Figure S3 H&E staining images of main organs (Scale bar = 50 μm). Figure S4 The percentages of CD44hiCD62Lhi among CD8+ T cells and CD4+ T cells in spleens after indicated treatment. Data were expressed as mean ± SEM (n  = 3, *P  < 0.05, **P  < 0.01, ***P  < 0.001 vs. RIMNA + Laser group). Figure S5 Flow cytometric analyses of (A) CD3+CD8+ T cells, (B) CD3+CD4+ T cells, (C) CD8+CD69+ T cells, (D) CD4+CD69+ T cells, (E) IFN-γ+CD8+ T cells, (F) CD4+Foxp3+ T cells, (G) CD8+CD44hiCD62Lhi  T cells and (H) CD4+CD44hiCD62Lhi T cells collected from spleens of tumor-bearing mice with different treatments.

Acknowledgements

Not applicable.

Author contributions

Chenlu Huang processed the data and wrote the manuscript. Chenlu Huang, Xinyu Yang and Huidong Li conducted the experiments. Li Zhang, Qing Guo and Qingyu Yu assisted some experiments. Hai Wang contributed to the collection of data related to flow cytometry. Linhua Zhang and Dunwan Zhu envisaged the study concept, supervised the research and edited the manuscript. All authors reviewed the manuscript.

Funding

This study was supported by National Natural Science Foundation of China (82172090, 82302390 and 82072059), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058 and 2022-I2M-2-003), China Postdoctoral Science Foundation (2022M720502), Natural Science Foundation of Tianjin Municipality (22JCQNJC00070), CAMS Union Young Scholars Support Program (2022051), and Fundamental Research Funds for the Central Universities (2019PT320028).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

All animals were treated according to the regulations and guidelines of the Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College. Extensive efforts were made to ensure minimal suffering of the animals used during the study.

Consent for publication

All authors approved the final manuscript and the submission to this journal.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Chenlu Huang, Xinyu Yang and Huidong Li have authors contributed equally to this work.
==== Refs
References

1. Fan W Yung B Huang P Chen X Nanotechnology for Multimodal Synergistic Cancer Therapy Chem Rev 2017 117 13566 638 10.1021/acs.chemrev.7b00258 29048884
Fan W, Yung B, Huang P, Chen X. Nanotechnology for Multimodal Synergistic Cancer Therapy. Chem Rev. 2017;117:13566–638.29048884 10.1021/acs.chemrev.7b00258
2. Chen J Zhu Y Wu C Shi J Nanoplatform-based Cascade Engineering for Cancer Therapy Chem Soc Rev 2020 49 9057 94 10.1039/D0CS00607F 33112326
Chen J, Zhu Y, Wu C, Shi J. Nanoplatform-based Cascade Engineering for Cancer Therapy. Chem Soc Rev. 2020;49:9057–94.33112326 10.1039/D0CS00607F
3. Liu Q Duo Y Fu J Qiu M Sun Z Adah D Kang J Xie Z Fan T Bao S Nano-immunotherapy: unique mechanisms of nanomaterials in Synergizing Cancer Immunotherapy Nano Today 2021 36 101023 10.1016/j.nantod.2020.101023
Liu Q, Duo Y, Fu J, Qiu M, Sun Z, Adah D, Kang J, Xie Z, Fan T, Bao S, et al. Nano-immunotherapy: unique mechanisms of nanomaterials in Synergizing Cancer Immunotherapy. Nano Today. 2021;36:101023.10.1016/j.nantod.2020.101023
4. Huang C Wang H Yang X Yu Q Wang H Zhang L Zhao Y Zhu D Cascade Carrier-Free nanoparticles forming in situ nanovaccines for synergistic Photothermal‐Immunotherapy of Cancer Adv Funct Mater 2024 34 2401489 10.1002/adfm.202401489
Huang C, Wang H, Yang X, Yu Q, Wang H, Zhang L, Zhao Y, Zhu D. Cascade Carrier-Free nanoparticles forming in situ nanovaccines for synergistic Photothermal‐Immunotherapy of Cancer. Adv Funct Mater. 2024;34:2401489.10.1002/adfm.202401489
5. Huang C Zhang L Guo Q Zuo Y Wang N Wang H Kong D Zhu D Zhang L Robust Nanovaccine based on polydopamine-coated mesoporous silica nanoparticles for effective Photothermal‐Immunotherapy against Melanoma Adv Funct Mater 2021 31 2010637 10.1002/adfm.202010637
Huang C, Zhang L, Guo Q, Zuo Y, Wang N, Wang H, Kong D, Zhu D, Zhang L. Robust Nanovaccine based on polydopamine-coated mesoporous silica nanoparticles for effective Photothermal‐Immunotherapy against Melanoma. Adv Funct Mater. 2021;31:2010637.10.1002/adfm.202010637
6. Xie Z Fan T An J Choi W Duo Y Ge Y Zhang B Nie G Xie N Zheng T Chen Y Zhang H Kim JS Emerging combination strategies with phototherapy in Cancer Nanomedicine Chem Soc Rev 2020 49 8065 87 10.1039/D0CS00215A 32567633
Xie Z, Fan T, An J, Choi W, Duo Y, Ge Y, Zhang B, Nie G, Xie N, Zheng T, Chen Y, Zhang H, Kim JS. Emerging combination strategies with phototherapy in Cancer Nanomedicine. Chem Soc Rev. 2020;49:8065–87.32567633 10.1039/D0CS00215A
7. Wang M Song J Zhou F Hoover AR Murray C Zhou B Wang L Qu J Chen WR NIR-Triggered Phototherapy and Immunotherapy via an Antigen-capturing nanoplatform for metastatic Cancer treatment Adv Sci (Weinh) 2019 6 1802157 10.1002/advs.201802157 31131193
Wang M, Song J, Zhou F, Hoover AR, Murray C, Zhou B, Wang L, Qu J, Chen WR. NIR-Triggered Phototherapy and Immunotherapy via an Antigen-capturing nanoplatform for metastatic Cancer treatment. Adv Sci (Weinh). 2019;6:1802157.31131193 10.1002/advs.201802157
8. Liang M Mu X Li Y Tan Y Hao X Tang Y Wang Z Feng W Lu Y Zhou X Heptamethine Cyanine-based nanotheranostics with catalase‐like activity for synergistic phototherapy of Cancer Adv Funct Mater 2023 33 2302112 10.1002/adfm.202302112
Liang M, Mu X, Li Y, Tan Y, Hao X, Tang Y, Wang Z, Feng W, Lu Y, Zhou X. Heptamethine Cyanine-based nanotheranostics with catalase‐like activity for synergistic phototherapy of Cancer. Adv Funct Mater. 2023;33:2302112.10.1002/adfm.202302112
9. Liu X Su H Shi W Liu Y Sun Y Ge D Functionalized poly(pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy Biomaterials 2018 167 177 90 10.1016/j.biomaterials.2018.03.030 29571053
Liu X, Su H, Shi W, Liu Y, Sun Y, Ge D. Functionalized poly(pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy. Biomaterials. 2018;167:177–90.29571053 10.1016/j.biomaterials.2018.03.030
10. Li X Lovell JF Yoon J Chen X Clinical Development and potential of Photothermal and Pphotodynamic therapies for Cancer Nat Rev Clin Oncol 2020 17 657 74 10.1038/s41571-020-0410-2 32699309
Li X, Lovell JF, Yoon J, Chen X. Clinical Development and potential of Photothermal and Pphotodynamic therapies for Cancer. Nat Rev Clin Oncol. 2020;17:657–74.32699309 10.1038/s41571-020-0410-2
11. Feng L Zhao R Yang L Liu B Dong S Qian C Liu J Zhao Y Tumor-specific NIR-Activatable nanoreactor for self-enhanced Multimodal Imaging and Cancer Phototherapy ACS Nano 2023 17 1622 37 10.1021/acsnano.2c11470
Feng L, Zhao R, Yang L, Liu B, Dong S, Qian C, Liu J, Zhao Y. Tumor-specific NIR-Activatable nanoreactor for self-enhanced Multimodal Imaging and Cancer Phototherapy. ACS Nano. 2023;17:1622–37.10.1021/acsnano.2c11470
12. Huang J Deng G Wang S Zhao T Chen Q Yang Y Yang Y Zhang J Nan Y Liu Z Cao K Huang Q Ai K A NIR-II photoactivatable ROS bomb with high‐density Cu2O‐Supported MoS2 Nanoflowers for Anticancer Therapy Adv Sci 2023 10 2302208 10.1002/advs.202302208
Huang J, Deng G, Wang S, Zhao T, Chen Q, Yang Y, Yang Y, Zhang J, Nan Y, Liu Z, Cao K, Huang Q, Ai K. A NIR-II photoactivatable ROS bomb with high‐density Cu2O‐Supported MoS2 Nanoflowers for Anticancer Therapy. Adv Sci. 2023;10:2302208.10.1002/advs.202302208
13. Yang L Huang B Hu S An Y Sheng J Li Y Wang Y Gu N Indocyanine Green Assembled Free Oxygen-nanobubbles towards enhanced Near-infrared Induced Photodynamic Therapy Nano Res 2022 15 4285 93 10.1007/s12274-022-4085-0 35126878
Yang L, Huang B, Hu S, An Y, Sheng J, Li Y, Wang Y, Gu N. Indocyanine Green Assembled Free Oxygen-nanobubbles towards enhanced Near-infrared Induced Photodynamic Therapy. Nano Res. 2022;15:4285–93.35126878 10.1007/s12274-022-4085-0
14. Zhou H Liao Y Han X Chen DS Hong X Zhou K Jiang X Xiao Y Shi J ROS-Responsive nanoparticle delivery of mRNA and photosensitizer for Combinatorial Cancer Therapy Nano Lett 2023 23 3661 8 10.1021/acs.nanolett.2c03784 37093620
Zhou H, Liao Y, Han X, Chen DS, Hong X, Zhou K, Jiang X, Xiao Y, Shi J. ROS-Responsive nanoparticle delivery of mRNA and photosensitizer for Combinatorial Cancer Therapy. Nano Lett. 2023;23:3661–8.37093620 10.1021/acs.nanolett.2c03784
15. Huang L Zhao S Wu J Yu L Singh N Yang K Lan M Wang P Kim JS Photodynamic therapy for hypoxic tumors: advances and perspectives Coord Chem Rev 2021 438 213888 10.1016/j.ccr.2021.213888
Huang L, Zhao S, Wu J, Yu L, Singh N, Yang K, Lan M, Wang P, Kim JS. Photodynamic therapy for hypoxic tumors: advances and perspectives. Coord Chem Rev. 2021;438:213888.10.1016/j.ccr.2021.213888
16. Zhang Y Liao Y Tang Q Lin J Huang P Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor Angew Chem Int Ed 2021 60 10647 53 10.1002/anie.202015590
Zhang Y, Liao Y, Tang Q, Lin J, Huang P. Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor. Angew Chem Int Ed. 2021;60:10647–53.10.1002/anie.202015590
17. Gao S Wang G Qin Z Wang X Zhao G Ma Q Zhu L Oxygen-generating Hybrid nanoparticles to enhance Fluorescent/photoacoustic/ultrasound imaging guided Tumor Photodynamic Therapy Biomaterials 2017 112 324 35 10.1016/j.biomaterials.2016.10.030 27776285
Gao S, Wang G, Qin Z, Wang X, Zhao G, Ma Q, Zhu L. Oxygen-generating Hybrid nanoparticles to enhance Fluorescent/photoacoustic/ultrasound imaging guided Tumor Photodynamic Therapy. Biomaterials. 2017;112:324–35.27776285 10.1016/j.biomaterials.2016.10.030
18. Peng J Yang Q Li W Tan L Xiao Y Chen L Hao Y Qian Z Erythrocyte-membrane-coated prussian Blue/Manganese Dioxide nanoparticles as H2O2-Responsive oxygen generators to enhance Cancer Chemotherapy/Photothermal Therapy ACS Appl Mater Interfaces 2017 9 44410 22 10.1021/acsami.7b17022 29210279
Peng J, Yang Q, Li W, Tan L, Xiao Y, Chen L, Hao Y, Qian Z. Erythrocyte-membrane-coated prussian Blue/Manganese Dioxide nanoparticles as H2O2-Responsive oxygen generators to enhance Cancer Chemotherapy/Photothermal Therapy. ACS Appl Mater Interfaces. 2017;9:44410–22.29210279 10.1021/acsami.7b17022
19. Qin Y Huang M Huang C Perry HL Zhang L Zhu D O2-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in Melanoma Chin Chem Lett 2023 35 109171 10.1016/j.cclet.2023.109171
Qin Y, Huang M, Huang C, Perry HL, Zhang L, Zhu D. O2-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in Melanoma. Chin Chem Lett. 2023;35:109171.10.1016/j.cclet.2023.109171
20. You Q Zhang K Liu J Liu C Wang H Wang M Ye S Gao H Lv L Wang C Zhu L Yang Y Persistent regulation of Tumor Hypoxia Microenvironment via a Bioinspired Pt-Based Oxygen Nanogenerator for Multimodal Imaging‐guided synergistic phototherapy Adv Sci 2020 7 1903341 10.1002/advs.201903341
You Q, Zhang K, Liu J, Liu C, Wang H, Wang M, Ye S, Gao H, Lv L, Wang C, Zhu L, Yang Y. Persistent regulation of Tumor Hypoxia Microenvironment via a Bioinspired Pt-Based Oxygen Nanogenerator for Multimodal Imaging‐guided synergistic phototherapy. Adv Sci. 2020;7:1903341.10.1002/advs.201903341
21. Zhang P Meng J Li Y Yang C Hou Y Tang W McHugh KJ Jing L Nanotechnology-enhanced Immunotherapy for Metastatic Cancer Innov (Camb) 2021 2 100174
Zhang P, Meng J, Li Y, Yang C, Hou Y, Tang W, McHugh KJ, Jing L. Nanotechnology-enhanced Immunotherapy for Metastatic Cancer. Innov (Camb). 2021;2:100174.
22. He T Hu M Zhu S Shen M Kou X Liang X Li L Li X Zhang M Wu Q Gong C A Tactical Nanomissile mobilizing Antitumor Immunity enables Neoadjuvant Chemo-Immunotherapy to Minimize Postsurgical Tumor Metastasis and Recurrence Acta Pharm Sin B 2023 13 804 18 10.1016/j.apsb.2022.09.017 36873172
He T, Hu M, Zhu S, Shen M, Kou X, Liang X, Li L, Li X, Zhang M, Wu Q, Gong C. A Tactical Nanomissile mobilizing Antitumor Immunity enables Neoadjuvant Chemo-Immunotherapy to Minimize Postsurgical Tumor Metastasis and Recurrence. Acta Pharm Sin B. 2023;13:804–18.36873172 10.1016/j.apsb.2022.09.017
23. Galon J Bruni D Approaches to treat Immune Hot, altered and cold tumours with combination immunotherapies Nat Rev Drug Discov 2019 18 197 218 10.1038/s41573-018-0007-y 30610226
Galon J, Bruni D. Approaches to treat Immune Hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.30610226 10.1038/s41573-018-0007-y
24. Zhou Y Liu S Hu C Cai L Pang M A covalent Organic Framework as a nanocarrier for synergistic phototherapy and immunotherapy J Mater Chem B 2020 8 5451 9 10.1039/D0TB00679C 32459249
Zhou Y, Liu S, Hu C, Cai L, Pang M. A covalent Organic Framework as a nanocarrier for synergistic phototherapy and immunotherapy. J Mater Chem B. 2020;8:5451–9.32459249 10.1039/D0TB00679C
25. Shen X Zhu C Wu Q Shi J Wu W Zhao X Sun J Li H Gu Z Nanomodulators targeting tumor-resident immunosuppressive cells: mechanisms and recent updates Nano Today 2022 47 101641 10.1016/j.nantod.2022.101641
Shen X, Zhu C, Wu Q, Shi J, Wu W, Zhao X, Sun J, Li H, Gu Z. Nanomodulators targeting tumor-resident immunosuppressive cells: mechanisms and recent updates. Nano Today. 2022;47:101641.10.1016/j.nantod.2022.101641
26. Zhang L Wu S Qin Y Fan F Zhang Z Huang C Ji W Lu L Wang C Sun H Leng X Kong D Zhu D Targeted codelivery of an Antigen and Dual agonists by Hybrid nanoparticles for enhanced Cancer Immunotherapy Nano Lett 2019 19 4237 49 10.1021/acs.nanolett.9b00030 30868883
Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, Ji W, Lu L, Wang C, Sun H, Leng X, Kong D, Zhu D. Targeted codelivery of an Antigen and Dual agonists by Hybrid nanoparticles for enhanced Cancer Immunotherapy. Nano Lett. 2019;19:4237–49.30868883 10.1021/acs.nanolett.9b00030
27. Zhu D Hu C Fan F Qin Y Huang C Zhang Z Lu L Wang H Sun H Leng X Wang C Kong D Zhang L Co-delivery of Antigen and dual agonists by programmed mannose-targeted Cationic lipid-hybrid polymersomes for enhanced vaccination Biomaterials 2019 206 25 40 10.1016/j.biomaterials.2019.03.012 30925286
Zhu D, Hu C, Fan F, Qin Y, Huang C, Zhang Z, Lu L, Wang H, Sun H, Leng X, Wang C, Kong D, Zhang L. Co-delivery of Antigen and dual agonists by programmed mannose-targeted Cationic lipid-hybrid polymersomes for enhanced vaccination. Biomaterials. 2019;206:25–40.30925286 10.1016/j.biomaterials.2019.03.012
28. Huang H Jiang C Shen S Liu A Gan Y Tong Q Chen S Gao Z Du J Cao J Wang J Nanoenabled reversal of IDO1-Mediated immunosuppression synergizes with immunogenic chemotherapy for Improved Cancer Therapy Nano Lett 2019 19 5356 65 10.1021/acs.nanolett.9b01807 31286779
Huang H, Jiang C, Shen S, Liu A, Gan Y, Tong Q, Chen S, Gao Z, Du J, Cao J, Wang J. Nanoenabled reversal of IDO1-Mediated immunosuppression synergizes with immunogenic chemotherapy for Improved Cancer Therapy. Nano Lett. 2019;19:5356–65.31286779 10.1021/acs.nanolett.9b01807
29. Han X Cheng K Xu Y Wang Y Min H Zhang Y Zhao X Zhao R Anderson GJ Ren L Nie G Li Y Modularly designed peptide Nanoprodrug augments Antitumor immunity of PD-L1 checkpoint blockade by Targeting Indoleamine 2,3-Dioxygenase J Am Chem Soc 2020 142 2490 6 10.1021/jacs.9b12232 31944687
Han X, Cheng K, Xu Y, Wang Y, Min H, Zhang Y, Zhao X, Zhao R, Anderson GJ, Ren L, Nie G, Li Y. Modularly designed peptide Nanoprodrug augments Antitumor immunity of PD-L1 checkpoint blockade by Targeting Indoleamine 2,3-Dioxygenase. J Am Chem Soc. 2020;142:2490–6.31944687 10.1021/jacs.9b12232
30. Peng J Xiao Y Li W Yang Q Tan L Jia Y Qu Y Qian Z Photosensitizer Micelles together with IDO inhibitor enhance Cancer Photothermal Therapy and Immunotherapy Adv Sci (Weinh) 2018 5 1700891 10.1002/advs.201700891 29876215
Peng J, Xiao Y, Li W, Yang Q, Tan L, Jia Y, Qu Y, Qian Z. Photosensitizer Micelles together with IDO inhibitor enhance Cancer Photothermal Therapy and Immunotherapy. Adv Sci (Weinh). 2018;5:1700891.29876215 10.1002/advs.201700891
31. Zhao Z Dong S Liu Y Wang J Ba L Zhang C Cao X Wu C Yang P Tumor Microenvironment-Activable Manganese-boosted Catalytic Immunotherapy combined with PD-1 checkpoint blockade ACS Nano 2022 16 20400 18 10.1021/acsnano.2c06646 36441901
Zhao Z, Dong S, Liu Y, Wang J, Ba L, Zhang C, Cao X, Wu C, Yang P. Tumor Microenvironment-Activable Manganese-boosted Catalytic Immunotherapy combined with PD-1 checkpoint blockade. ACS Nano. 2022;16:20400–18.36441901 10.1021/acsnano.2c06646
32. Hu Y Lin L Guo Z Chen J Maruyama A Tian H Chen X In situ vaccination and gene-mediated PD-L1 blockade for enhanced Tumor Immunotherapy Chin Chem Lett 2021 32 1770 4 10.1016/j.cclet.2020.12.055
Hu Y, Lin L, Guo Z, Chen J, Maruyama A, Tian H, Chen X. In situ vaccination and gene-mediated PD-L1 blockade for enhanced Tumor Immunotherapy. Chin Chem Lett. 2021;32:1770–4.10.1016/j.cclet.2020.12.055
33. Hu C Song Y Zhang Y He S Liu X Yang X Gong T Huang Y Gao H Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for Immunosuppressive Microenvironment Remodeling via an MMP-2 responsive dual-targeting Liposome Acta Pharm Sin B 2023 13 2176 87 10.1016/j.apsb.2023.02.009 37250156
Hu C, Song Y, Zhang Y, He S, Liu X, Yang X, Gong T, Huang Y, Gao H. Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for Immunosuppressive Microenvironment Remodeling via an MMP-2 responsive dual-targeting Liposome. Acta Pharm Sin B. 2023;13:2176–87.37250156 10.1016/j.apsb.2023.02.009
34. Panda A Ganesan S Genomic and immunologic correlates of indoleamine 2,3-Dioxygenase pathway expression in Cancer Front Genet 2021 12 706435 10.3389/fgene.2021.706435 34367262
Panda A, Ganesan S. Genomic and immunologic correlates of indoleamine 2,3-Dioxygenase pathway expression in Cancer. Front Genet. 2021;12:706435.34367262 10.3389/fgene.2021.706435
35. Li X Zhou X Liu J Zhang J Feng Y Wang F He Y Wan A Filipczak N Yalamarty SSK Jin Y Torchilin VP Liposomal co-delivery of PD-L1 siRNA/Anemoside B4 for enhanced Combinational Immunotherapeutic Effect ACS Appl Mater Interfaces 2022 14 28439 54 10.1021/acsami.2c01123 35726706
Li X, Zhou X, Liu J, Zhang J, Feng Y, Wang F, He Y, Wan A, Filipczak N, Yalamarty SSK, Jin Y, Torchilin VP. Liposomal co-delivery of PD-L1 siRNA/Anemoside B4 for enhanced Combinational Immunotherapeutic Effect. ACS Appl Mater Interfaces. 2022;14:28439–54.35726706 10.1021/acsami.2c01123
36. Liu Y-T Sun Z-J Turning Cold tumors into hot tumors by improving T-cell infiltration Theranostics 2021 11 5365 86 10.7150/thno.58390 33859752
Liu Y-T, Sun Z-J. Turning Cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365–86.33859752 10.7150/thno.58390
37. Ma S Tian Z Liu L Zhu J Wang J Zhao S Zhu Y Zhu J Wang W Jiang R Qu Y Lei J Zhao J Jiang T Cold to Hot: Tumor Immunotherapy by promoting vascular normalization based on PDGFB nanocomposites Small 2023 20 2308638 10.1002/smll.202308638
Ma S, Tian Z, Liu L, Zhu J, Wang J, Zhao S, Zhu Y, Zhu J, Wang W, Jiang R, Qu Y, Lei J, Zhao J, Jiang T. Cold to Hot: Tumor Immunotherapy by promoting vascular normalization based on PDGFB nanocomposites. Small. 2023;20:2308638.10.1002/smll.202308638
38. Lan X Liang J Wen C Quan X Lin H Xu Q Chen P Yao G Zhou D Yu M Photo-manipulated Polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy Chin Chem Lett 2023 35 108616 10.1016/j.cclet.2023.108616
Lan X, Liang J, Wen C, Quan X, Lin H, Xu Q, Chen P, Yao G, Zhou D, Yu M. Photo-manipulated Polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chin Chem Lett. 2023;35:108616.10.1016/j.cclet.2023.108616
39. Yang X Huang C Wang H Yang K Huang M Zhang W Yu Q Wang H Zhang L Zhao Y Zhu D Multifunctional nanoparticle-loaded Injectable Alginate Hydrogels with Deep Tumor Penetration for enhanced chemo-immunotherapy of Cancer ACS Nano 2024 18 18604 21 10.1021/acsnano.4c04766 38952130
Yang X, Huang C, Wang H, Yang K, Huang M, Zhang W, Yu Q, Wang H, Zhang L, Zhao Y, Zhu D. Multifunctional nanoparticle-loaded Injectable Alginate Hydrogels with Deep Tumor Penetration for enhanced chemo-immunotherapy of Cancer. ACS Nano. 2024;18:18604–21.38952130 10.1021/acsnano.4c04766
40. Li Z Fan F Ma J Yin W Zhu D Zhang L Wang Z Oxygen- and bubble-generating polymersomes for Tumor-targeted and enhanced photothermal–photodynamic combination therapy Biomater Sci 2021 9 5841 53 10.1039/D1BM00659B 34269778
Li Z, Fan F, Ma J, Yin W, Zhu D, Zhang L, Wang Z. Oxygen- and bubble-generating polymersomes for Tumor-targeted and enhanced photothermal–photodynamic combination therapy. Biomater Sci. 2021;9:5841–53.34269778 10.1039/D1BM00659B
41. Liang X Ye X Wang C Xing C Miao Q Xie Z Chen X Zhang X Zhang H Mei L Photothermal Cancer Immunotherapy by Erythrocyte membrane-coated Black Phosphorus Formulation J Control Release 2019 296 150 61 10.1016/j.jconrel.2019.01.027 30682441
Liang X, Ye X, Wang C, Xing C, Miao Q, Xie Z, Chen X, Zhang X, Zhang H, Mei L. Photothermal Cancer Immunotherapy by Erythrocyte membrane-coated Black Phosphorus Formulation. J Control Release. 2019;296:150–61.30682441 10.1016/j.jconrel.2019.01.027
42. Wang L Mao Z Wu J Cui X Wang Y Yang N Ge J Lei H Han Z Tang W Guan S Cheng L Engineering Layered double hydroxide-based sonocatalysts for enhanced Sonodynamic-Immunotherapy Nano Today 2023 49 101782 10.1016/j.nantod.2023.101782
Wang L, Mao Z, Wu J, Cui X, Wang Y, Yang N, Ge J, Lei H, Han Z, Tang W, Guan S, Cheng L. Engineering Layered double hydroxide-based sonocatalysts for enhanced Sonodynamic-Immunotherapy. Nano Today. 2023;49:101782.10.1016/j.nantod.2023.101782
43. Ding B Zheng P Ma Pa, Lin J Manganese oxide nanomaterials: synthesis, Properties, and Theranostic Applications Adv Mater 2020 32 1905823 10.1002/adma.201905823
Ding B, Zheng P, Ma Pa, Lin J. Manganese oxide nanomaterials: synthesis, Properties, and Theranostic Applications. Adv Mater. 2020;32:1905823.10.1002/adma.201905823
44. Qi S Wang Y Zhu Y Zhang X Wang X Yu X Yang K Bai B Feng Y Lei J Zhang K Lu Z Zhu S Du J Yu G NIR-II Fluorescence Lymphatic Imaging and intraoperative Navigation based on the isolated cage Monodisperse Strategy Nano Today 2023 49 101795 10.1016/j.nantod.2023.101795
Qi S, Wang Y, Zhu Y, Zhang X, Wang X, Yu X, Yang K, Bai B, Feng Y, Lei J, Zhang K, Lu Z, Zhu S, Du J, Yu G. NIR-II Fluorescence Lymphatic Imaging and intraoperative Navigation based on the isolated cage Monodisperse Strategy. Nano Today. 2023;49:101795.10.1016/j.nantod.2023.101795
45. Yang L Hou X Zhang Y Wang D Liu J Huang F Liu J NIR-activated self-sensitized polymeric micelles for enhanced Cancer Chemo-Photothermal Therapy J Control Release 2021 339 114 29 10.1016/j.jconrel.2021.09.017 34536448
Yang L, Hou X, Zhang Y, Wang D, Liu J, Huang F, Liu J. NIR-activated self-sensitized polymeric micelles for enhanced Cancer Chemo-Photothermal Therapy. J Control Release. 2021;339:114–29.34536448 10.1016/j.jconrel.2021.09.017
46. Tang F Ding A Xu Y Ye Y Li L Xie R Huang W Gene and Photothermal Combination Therapy: Principle, materials, and amplified anticancer intervention Small 2023 20 2307078 10.1002/smll.202307078
Tang F, Ding A, Xu Y, Ye Y, Li L, Xie R, Huang W. Gene and Photothermal Combination Therapy: Principle, materials, and amplified anticancer intervention. Small. 2023;20:2307078.10.1002/smll.202307078
47. Wen J Yang K Sun S MnO2-based nanosystems for Cancer Therapy Cheml Commun 2020 56 7065 79 10.1039/D0CC02782K
Wen J, Yang K, Sun S. MnO2-based nanosystems for Cancer Therapy. Cheml Commun. 2020;56:7065–79.10.1039/D0CC02782K
48. Wang Y Gou M Gong C Wang C Qian Z Lin YF Luo F Pharmacokinetics and Disposition of Nanomedicine using biodegradable PEG/PCL polymers as drug carriers Curr Drug Metab 2012 13 338 53 10.2174/138920012800166490 22443531
Wang Y, Gou M, Gong C, Wang C, Qian Z, Lin YF, Luo F. Pharmacokinetics and Disposition of Nanomedicine using biodegradable PEG/PCL polymers as drug carriers. Curr Drug Metab. 2012;13:338–53.22443531 10.2174/138920012800166490
49. Kwon N Jasinevicius GO Kassab G Ding L Bu J Martinelli LP Ferreira VG Dhaliwal A Chan HHL Mo Y Bagnato VS Kurachi C Chen J Zheng G Buzza HH Nanostructure-driven Indocyanine Green Dimerization generates Ultra‐stable phototheranostics nanoparticles Angew Chem Int Ed 2023 62 e202305564 10.1002/anie.202305564
Kwon N, Jasinevicius GO, Kassab G, Ding L, Bu J, Martinelli LP, Ferreira VG, Dhaliwal A, Chan HHL, Mo Y, Bagnato VS, Kurachi C, Chen J, Zheng G, Buzza HH. Nanostructure-driven Indocyanine Green Dimerization generates Ultra‐stable phototheranostics nanoparticles. Angew Chem Int Ed. 2023;62:e202305564.10.1002/anie.202305564
50. Gao Y Ouyang Z Shen S Yu H Jia B Wang H Shen M Shi X Manganese dioxide-entrapping dendrimers co-deliver protein and Nucleotide for Magnetic Resonance Imaging-Guided Chemodynamic/Starvation/Immune Therapy of Tumors ACS Nano 2023 17 23889 902 10.1021/acsnano.3c08174 38006397
Gao Y, Ouyang Z, Shen S, Yu H, Jia B, Wang H, Shen M, Shi X. Manganese dioxide-entrapping dendrimers co-deliver protein and Nucleotide for Magnetic Resonance Imaging-Guided Chemodynamic/Starvation/Immune Therapy of Tumors. ACS Nano. 2023;17:23889–902.38006397 10.1021/acsnano.3c08174
51. Gilani SJ Ameeduzzafar, Jafar M Shakil K Imam SS Nano-carriers for the treatment of tuberculosis Recent Pat Antiinfect Drug Discov 2017 12 95 106 10.2174/1574891X12666170427120230 28595544
Gilani SJ, Ameeduzzafar, Jafar M, Shakil K, Imam SS. Nano-carriers for the treatment of tuberculosis. Recent Pat Antiinfect Drug Discov. 2017;12:95–106.28595544 10.2174/1574891X12666170427120230
52. Dai Y Wang B Sun Z Cheng J Zhao H Wu K Sun P Shen Q Li M Fan Q Multifunctional theranostic liposomes loaded with a hypoxia-activated Prodrug for Cascade-activated Tumor Selective Combination Therapy ACS Appl Mater Interfaces 2019 11 39410 23 10.1021/acsami.9b11080 31578854
Dai Y, Wang B, Sun Z, Cheng J, Zhao H, Wu K, Sun P, Shen Q, Li M, Fan Q. Multifunctional theranostic liposomes loaded with a hypoxia-activated Prodrug for Cascade-activated Tumor Selective Combination Therapy. ACS Appl Mater Interfaces. 2019;11:39410–23.31578854 10.1021/acsami.9b11080
53. Liu J Zhang Y Yang B Jia Y Liu RT Ding L Shen Z Chen X Synergistic glutathione depletion and STING activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy Angew Chem Int Ed 2024 63 e202318530 10.1002/anie.202318530
Liu J, Zhang Y, Yang B, Jia Y, Liu RT, Ding L, Shen Z, Chen X. Synergistic glutathione depletion and STING activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy. Angew Chem Int Ed. 2024;63:e202318530.10.1002/anie.202318530
54. Wang N Zuo Y Wu S Huang C Zhang L Zhu D Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing Antigen-specific Immune responses Acta Pharm Sin B 2022 12 4486 500 10.1016/j.apsb.2022.05.032 36561992
Wang N, Zuo Y, Wu S, Huang C, Zhang L, Zhu D. Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing Antigen-specific Immune responses. Acta Pharm Sin B. 2022;12:4486–500.36561992 10.1016/j.apsb.2022.05.032
55. Zhou M Liang S Liu D Ma K Yun K Yao J Peng Y Hai L Zhang Q Wang Z Manganese-enriched zinc Peroxide Functional nanoparticles for Potentiating Cancer Immunotherapy Nano Lett 2023 23 10350 9 10.1021/acs.nanolett.3c02941 37930173
Zhou M, Liang S, Liu D, Ma K, Yun K, Yao J, Peng Y, Hai L, Zhang Q, Wang Z. Manganese-enriched zinc Peroxide Functional nanoparticles for Potentiating Cancer Immunotherapy. Nano Lett. 2023;23:10350–9.37930173 10.1021/acs.nanolett.3c02941
56. Ou W Thapa RK Jiang L Soe ZC Gautam M Chang JH Jeong JH Ku SK Choi HG Yong CS Kim JO Regulatory T cell-targeted hybrid nanoparticles combined with Immuno-checkpoint blockage for Cancer Immunotherapy J Control Release 2018 281 84 96 10.1016/j.jconrel.2018.05.018 29777794
Ou W, Thapa RK, Jiang L, Soe ZC, Gautam M, Chang JH, Jeong JH, Ku SK, Choi HG, Yong CS, Kim JO. Regulatory T cell-targeted hybrid nanoparticles combined with Immuno-checkpoint blockage for Cancer Immunotherapy. J Control Release. 2018;281:84–96.29777794 10.1016/j.jconrel.2018.05.018
57. Yu G Jung H Kang YY Mok H Comparative evaluation of cell- and serum-derived exosomes to deliver Immune stimulators to lymph nodes Biomaterials 2018 162 71 81 10.1016/j.biomaterials.2018.02.003 29438882
Yu G, Jung H, Kang YY, Mok H. Comparative evaluation of cell- and serum-derived exosomes to deliver Immune stimulators to lymph nodes. Biomaterials. 2018;162:71–81.29438882 10.1016/j.biomaterials.2018.02.003
58. Kinjyo I Qin J Tan SY Wellard CJ Mrass P Ritchie W Doi A Cavanagh LL Tomura M Sakaue-Sawano A Kanagawa O Miyawaki A Hodgkin PD Weninger W Real-time Tracking of Cell Cycle Progression during CD8+ effector and memory T-cell differentiation Nat Commun 2015 6 6301 10.1038/ncomms7301 25709008
Kinjyo I, Qin J, Tan SY, Wellard CJ, Mrass P, Ritchie W, Doi A, Cavanagh LL, Tomura M, Sakaue-Sawano A, Kanagawa O, Miyawaki A, Hodgkin PD, Weninger W. Real-time Tracking of Cell Cycle Progression during CD8+ effector and memory T-cell differentiation. Nat Commun. 2015;6:6301.25709008 10.1038/ncomms7301
59. Xiao Z Su Z Han S Huang J Lin L Shuai X Dual pH-sensitive Nanodrug blocks PD-1 Immune Checkpoint and uses T cells to deliver NF-kappaB inhibitor for Antitumor Immunotherapy Sci Adv 2020 6 eaay7785 10.1126/sciadv.aay7785 32076650
Xiao Z, Su Z, Han S, Huang J, Lin L, Shuai X. Dual pH-sensitive Nanodrug blocks PD-1 Immune Checkpoint and uses T cells to deliver NF-kappaB inhibitor for Antitumor Immunotherapy. Sci Adv. 2020;6:eaay7785.32076650 10.1126/sciadv.aay7785
60. Farhood B Najafi M Mortezaee K CD8+ cytotoxic T lymphocytes in Cancer Immunotherapy: a review J Cell Physiol 2019 234 8509 21 10.1002/jcp.27782 30520029
Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in Cancer Immunotherapy: a review. J Cell Physiol. 2019;234:8509–21.30520029 10.1002/jcp.27782
